Vohra Ravinder S, Hodson James, Pasquali Sandro, Griffiths Ewen A
Nottingham Oesophago-Gastric Unit, Nottingham University Hospitals NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK.
Institute of Translational Medicine (ITM), University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2G, UK.
World J Surg. 2017 Sep;41(9):2231-2239. doi: 10.1007/s00268-017-4018-3.
There is a variation in the administration of antibiotics prophylaxis to reduce the perceived risk of SSI in patients undergoing non-emergency cholecystectomy. The aim of this study was to determine the effectiveness of antibiotic prophylaxis following non-emergency cholecystectomy to prevent 30-day superficial surgical site infections (SSIs) using non-selected, nationally collected, prospective data.
Data were extracted from the CholeS study, which examined and independently validated the outcomes on consecutive patients following non-emergency cholecystectomy across 166 hospitals in the UK and Ireland. Patients who received antibiotic prophylaxis were exact matched to those who did not on variables associated with antibiotic prophylaxis. The primary outcome of interest was superficial SSI, and secondary outcomes included deep SSI, readmissions, complications and re-interventions within 30 days.
Out of a total of 7327 patients included in the study, 4468 (61%) received antibiotic prophylaxis. These were matched to patients who did not receive antibiotic prophylaxis on a range of demographic and surgical factors, leaving 1269 pairs of patients for analysis. Within this cohort, patients receiving antibiotic prophylaxis had significantly lower rates of superficial SSI (0.7% vs. 2.3%, p = 0.001) and all-cause complications (5.8 vs. 8.0%, p = 0.031), but similar rates of deep SSI (1.0 vs. 1.4%, p = 0.473), readmissions (5.2 vs. 6.2%, p = 0.302) and re-interventions (2.6 vs. 3.7%, p = 0.093). The number needed to treat to prevent one superficial SSI was 45 (95% confidence interval 24-662).
Antibiotics appear effective at reducing SSI after non-emergency cholecystectomy. However, due to the high number needed to treat it is unclear whether they provide a worthwhile clinical benefit to patients.
在非急诊胆囊切除术患者中,为降低手术部位感染(SSI)的可感知风险,抗生素预防的使用存在差异。本研究的目的是利用未筛选的、全国收集的前瞻性数据,确定非急诊胆囊切除术后抗生素预防对预防30天浅表手术部位感染(SSI)的有效性。
数据取自CholeS研究,该研究对英国和爱尔兰166家医院连续进行非急诊胆囊切除术后患者的结局进行了检查和独立验证。接受抗生素预防的患者在与抗生素预防相关的变量上与未接受预防的患者进行精确匹配。感兴趣的主要结局是浅表SSI,次要结局包括深部SSI、再入院、并发症以及30天内的再次干预。
在纳入研究的总共7327例患者中,4468例(61%)接受了抗生素预防。这些患者在一系列人口统计学和手术因素上与未接受抗生素预防的患者进行了匹配,留下1269对患者进行分析。在该队列中,接受抗生素预防的患者浅表SSI发生率显著较低(0.7%对2.3%,p = 0.001)和全因并发症发生率较低(5.8%对8.0%,p = 0.031),但深部SSI发生率相似(1.0%对1.4%,p = 0.473)、再入院率相似(5.2%对6.2%,p = 0.302)以及再次干预率相似(2.6%对3.7%,p = 0.093)。预防一例浅表SSI所需治疗的患者数为45例(95%置信区间24 - 662)。
抗生素似乎对降低非急诊胆囊切除术后的SSI有效。然而,由于所需治疗的患者数较多,尚不清楚它们是否能为患者提供有价值的临床益处。